Don't mistake Stryker's latest $500 million deal in the spine market as a simple tuck-in acquisition, says one analyst while another says it could help Stryker give Medtronic a run for its money.
The acquisition price for the Israeli company was $110 million in upfront cash payments with the potential for an additional $110 million upon meeting certain commercial milestones.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Analysts say that Stryker's purchase of a small but fast-growing public company in the complex spine market should help its own struggling spine business.
Stryker is shelling out top dollar to buy Novadaq, a maker of fluorescence imaging technologies that allows surgeons to see blood flow in vessels during surgery in real time.
Orthopedics heavyweight Stryker is leveraging Microsoft's Microsoft HoloLens holographic technology to reimagine the operating room and bring efficiencies to hospitals.
The shift from volume to value is no where more apparent than in the orthopedics specialty where vendors that once obsessed over titanium and steel are now focusing on services to manage the bundled payment era.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
As the buzz around robotics grows, J&J 's DePuy Synthes is touting the clinical and economic evidence tied to its non-robotic knee platform to help hospitals navigate the bundled payments era, but will that sway them?
Stryker is launching its Triathlon total knee on its Mako robotic system, reportedly priced at $1 million, at a time of bundled payments and cost consciousness in joint replacement procedures.
Zimmer Biomet just acquired a telerehab startup, RespondWell, to play in a different part of the bundle as it relates to the Comprehensive Care for Joint Replacement program for hip and knee replacements. Stryker is not interested in such technology.
Smart medtech companies are realizing that they have to be partners to hospitals and not simply vendors selling widgets.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
The SurgiCount product has been available for years, but Stryker is now standing by its product in a unique and perhaps rarely confident way. The device company is calling it the SurgiCount Promise.
Washington-based Physio-Control will be integrated into Stryker’s emergency medical systems portfolio.
Neurotechnology, mobility and robotics are the main focuses for Stryker moving forward.
MedReps.com surveyed 1,400 members of the site’s community, who currently work or recently worked in medical sales, to determine which companies are the best to work for overall. Best medical device company: Medtronic. Stryker and Johnson & Johnson ranked second and third. Best pharma company: Johnson & Johnson. Pfizer and Eli Lilly ranked second and […]
Stryker Corp.’s OtisMed unit will pay $80 million in fines because the division distributed its knee replacement surgery devices without regulatory approval in 2009. Stryker said in a statement that the DOJ acknowledged that OtisMed’s criminal conduct “occurred prior to Stryker’s acquisition of OtisMed and without Stryker’s prior knowledge or acquiescence.” Bloomberg says: OtisMed will pay a fine of $34.4 million […]